Cardiovascular disease
Cereno builds momentum for major clinical milestones
Cereno Scientific has announced clear progress in its Phase II clinical trial with the lead drug candidate CS1. The study, which includes...
Cereno Scientific strengthens CS1 patent protection in Japan
At the end of 2021, Cereno Scientific received its...
Cereno Scientific faces an eventful 2022
2021 brought significant progress for Cereno Scientific. The company...
Intervju
Cereno Scientific adds new candidate to the pipeline
Cereno Scientific's collaboration with top-ranked University of Michigan...
Cereno Scientific strengthens its patent protection
Patent protection for Cereno Scientific's primary asset, CS1, was strengthened...
Intervju